Rockefeller Capital Management
CRSP icon

Rockefeller Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Rockefeller Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.49M Sell
73,325
-39,342
-35% -$2.08M 0.01% 1066
2025
Q4 		$5.91M Sell
112,667
-35,864
-24% -$2.15M 0.01% 821
2025
Q3 		$9.63M Buy
148,531
+33,175
+29% +$1.9M 0.02% 632
2025
Q2 		$5.61M Buy
115,356
+24,853
+27% +$962K 0.01% 755
2025
Q1 		$3.08M Buy
90,503
+931
+1% +$39.5K 0.01% 881
2024
Q4 		$3.53M Sell
89,572
-3,295
-4% -$156K 0.01% 830
2024
Q3 		$4.36M Sell
92,867
-1,160
-1% -$58.9K 0.01% 751
2024
Q2 		$5.08M Buy
94,027
+14,907
+19% +$862K 0.01% 681
2024
Q1 		$5.39M Sell
79,120
-975
-1% -$69.8K 0.02% 671
2023
Q4 		$5.01M Buy
80,095
+5,621
+8% +$311K 0.02% 634
2023
Q3 		$3.38M Buy
74,474
+916
+1% +$47.3K 0.01% 679
2023
Q2 		$4.13M Sell
73,558
-3,618
-5% -$205K 0.02% 637
2023
Q1 		$3.49M Sell
77,176
-3,590
-4% -$174K 0.02% 646
2022
Q4 		$3.28M Sell
80,766
-14,666
-15% -$778K 0.02% 611
2022
Q3 		$6.24M Buy
95,432
+80,146
+524% +$5.81M 0.03% 476
2022
Q2 		$928K Sell
15,286
-8,432
-36% -$496K ﹤0.01% 1021
2022
Q1 		$1.49M Buy
23,718
+56
+0.2% +$3.52K 0.01% 913
2021
Q4 		$1.79M Buy
23,662
+6,569
+38% +$574K 0.01% 838
2021
Q3 		$1.91M Buy
17,093
+13,550
+382% +$1.7M 0.01% 770
2021
Q2 		$573K Sell
3,543
-1,053
-23% -$128K ﹤0.01% 1147
2021
Q1 		$560K Sell
4,596
-1,242
-21% -$188K ﹤0.01% 983
2020
Q4 		$893K Buy
5,838
+1,321
+29% +$156K 0.01% 721
2020
Q3 		$377K Buy
4,517
+802
+22% +$71.1K ﹤0.01% 864
2020
Q2 		$273K Buy
3,715
+2,000
+117% +$117K ﹤0.01% 870
2020
Q1 		$72K Sell
1,715
-132
-7% -$6.82K ﹤0.01% 1125
2019
Q4 		$112K Sell
1,847
-25
-1% -$1.36K ﹤0.01% 925
2019
Q3 		$77K Sell
1,872
-107
-5% -$5.11K ﹤0.01% 856
2019
Q2 		$93K Hold
1,979
– – ﹤0.01% 704
2019
Q1 		$71K Hold
1,979
– – ﹤0.01% 836
2018
Q4 		$57K Hold
1,979
– – ﹤0.01% 506
2018
Q3 		$88K Hold
1,979
– – ﹤0.01% 401
2018
Q2 		$116K Buy
+1,979
New +$113K ﹤0.01% 372

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rockefeller Capital Management's CRSP Position: Q1 2026 in Review

Rockefeller Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 35% in Q1 2026, selling an estimated $2.08M and leaving 73,325 shares worth $3.49M. The position accounts for 0.01% of the portfolio, ranked #1066.

Rockefeller Capital Management first reported a position in CRSP in Q2 2018 and has held it in 32 quarters since. The position peaked at $9.63M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Rockefeller Capital Management held 73,325 shares of CRISPR Therapeutics worth $3.49M as of Q1 2026.
  • Rockefeller Capital Management sold 39,342 CRISPR Therapeutics shares in Q1 2026, an estimated $2.08M.
  • CRISPR Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1066 holding.
  • Rockefeller Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Rockefeller Capital Management's CRISPR Therapeutics position peaked at $9.63M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.